Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature-Reference-Cited by-同舟云学术

Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature

Published:2012-02-27 Issue:11 Volume:109 Page:4257-4262
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proceedings of the National Academy of Sciences

Author:

Serra-Nedelec A. D. R.,Edouard T.,Treguer K.,Tajan M.,Araki T.,Dance M.,Mus M.,Montagner A.,Tauber M.,Salles J.-P.,Valet P.,Neel B. G.,Raynal P.,Yart A.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference35 articles.

1. Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines

2. Noonan syndrome and clinically related disorders

3. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation

4. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome

5. How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Braf-mutant Schwann cells divert to a repair phenotype to induce congenital demyelinating neuropathy;2024-04-25

2. Genetic backgrounds and genotype-phenotype relationships in anthropometric parameters of 116 Japanese individuals with Noonan syndrome;CLIN PEDIATR ENDOCRI;2024

3. Spectrum of Mutations in PTPN11 in Russian Cohort;Genes;2024-03-07

4. Interactions between Ras and Rap signaling pathways during neurodevelopment in health and disease;Frontiers in Molecular Neuroscience;2024-02-23

5. Neuroimmune pathways involvement in neurodegeneration of R6/2 mouse model of Huntington’s disease;Frontiers in Cellular Neuroscience;2024-02-20